停用与继续使用ACEI/ARB对COVID-19住院患者存活且出院天数的影响:随机临床试验
该随机临床试验纳入659例住院前正在服用ACEI或ARB的轻中度COVID-19住院患者,比较停用与继续用药对30天内存活且出院天数的影响。结果显示两组平均存活且出院天数无显著差异(均值比0.95,95%CI 0.90-1.01)。结论不支持对有适应证的轻中度COVID-19住院患者常规停用ACEI/ARB。
要点
- 停用与继续ACEI/ARB的30天存活且出院天数无显著差异。
- 死亡、心血管死亡及COVID-19进展风险两组间均无统计学差异。
- 有治疗指征时,轻中度COVID-19住院患者不必常规停用ACEI/ARB。
核心结论
- 在住院前服用ACEI或ARB的轻中度COVID-19住院患者中,停用与继续用药的30天内平均存活且出院天数无显著差异。
- 研究结果不支持对有治疗指征的此类患者常规停用ACEI或ARB。
研究设计与样本
- 随机临床试验,纳入659例巴西住院的轻中度COVID-19患者,住院前正在服用ACEI或ARB。
- 患者随机分为停用组(n=334)与继续组(n=325),随访至30天。
主要发现
- 停用组平均存活且出院天数为21.9天(SD 8天),继续组为22.9天(SD 7.1天),均值比0.95(95%CI 0.90-1.01)。
- 死亡:停用组2.7% vs 继续组2.8%,OR 0.97(95%CI 0.38-2.52)。
- 心血管死亡:0.6% vs 0.3%,OR 1.95(95%CI 0.19-42.12)。
- COVID-19进展:38.3% vs 32.3%,OR 1.30(95%CI 0.95-1.80)。
临床怎么用
- 对于因轻中度COVID-19住院且住院前服用ACEI或ARB的患者,若存在治疗指征,可继续用药而不必常规停用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: It is unknown whether angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) have a positive, neutral, or negative effect on clinical outcomes in patients with coronavirus disease 2019 (COVID-19). OBJECTIVE: To determine whether discontinuation compared with continuation of ACEIs or ARBs changed the number of days alive and out of the hospital through 30 days. DESIGN, SETTING, AND PARTICIPANTS: A randomized clinical trial of 659 patients hospitalized in Brazil with mild to moderate COVID-19 who were taking ACEIs or ARBs prior to hospitalization (enrolled: April 9-June 26, 2020; final follow-up: July 26, 2020). INTERVENTIONS: Discontinuation (n = 334) or continuation (n = 325) of ACEIs or ARBs. MAIN OUTCOMES AND MEASURES: The primary outcome was the number of days alive and out of the hospital through 30 days. Secondary outcomes included death, cardiovascular death, and COVID-19 progression. RESULTS: Among 659 patients, the median age was 55.1 years (interquartile range [IQR], 46.1-65.0 years), 14.7% were aged 70 years or older, 40.4% were women, and 100% completed the trial. The median time from symptom onset to hospital admission was 6 days (IQR, 4-9 days) and 27.2% of patients had an oxygen saturation of less than 94% of room air at baseline. In terms of clinical severity, 57.1% of patients were considered mild at hospital admission and 42.9% were considered moderate. There was no significant difference in the number of days alive and out of the hospital in patients in the discontinuation group (mean, 21.9 days [SD, 8 days]) vs patients in the continuation group (mean, 22.9 days [SD, 7.1 days]) and the mean ratio was 0.95 (95% CI, 0.90-1.01). There also was no statistically significant difference in death (2.7% for the discontinuation group vs 2.8% for the continuation group; odds ratio [OR], 0.97 [95% CI, 0.38-2.52]), cardiovascular death (0.6% vs 0.3%, respectively; OR, 1.95 [95% CI, 0.19-42.12]), or COVID-19 progression (38.3% vs 32.3%; OR, 1.30 [95% CI, 0.95-1.80]). The most common adverse events were respiratory failure requiring invasive mechanical ventilation (9.6% in the discontinuation group vs 7.7% in the continuation group), shock requiring vasopressors (8.4% vs 7.1%, respectively), acute myocardial infarction (7.5% vs 4.6%), new or worsening heart failure (4.2% vs 4.9%), and acute kidney failure requiring hemodialysis (3.3% vs 2.8%). CONCLUSIONS AND RELEVANCE: Among patients hospitalized with mild to moderate COVID-19 and who were taking ACEIs or ARBs before hospital admission, there was no significant difference in the mean number of days alive and out of the hospital for those assigned to discontinue vs continue these medications. These findings do not support routinely discontinuing ACEIs or ARBs among patients hospitalized with mild to moderate COVID-19 if there is an indication for treatment. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04364893.
引用
- Lopes RD, Macedo AVS, de Barros E Silva PGM, et al. Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial. JAMA. 2021. PMID: 33464336. doi:10.1001/jama.2020.25864
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。